Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- NKTX
- Price
- 2.40
- Stock movement up
- +0.20 (9.09%)
- Company name
- Nkarta Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 170.47M
- Ent value
- 199.69M
- Price/Sales
- 18.87
- Price/Book
- 0.50
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -17.49%
- 1 year return (CAGR)
- -1.64%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NKTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 18.87 |
| Price to Book | 0.50 |
| EV to Sales | 22.10 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 71.03M |
| EPS (TTM) | -1.39 |
| FCF per share (TTM) | -1.26 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 9.03M |
| Gross profit (TTM) | -113.00K |
| Operating income (TTM) | -121.96M |
| Net income (TTM) | -102.61M |
| EPS (TTM) | -1.39 |
| EPS (1y forward) | -1.31 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -1.25% |
| Operating margin (TTM) | -1350.00% |
| Profit margin (TTM) | -1135.82% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 60.11M |
| Net receivables | 0.00 |
| Total current assets | 289.27M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 129.76M |
| Total assets | 427.24M |
| Accounts payable | 1.44M |
| Short/Current long term debt | 76.63M |
| Total current liabilities | 18.99M |
| Total liabilities | 89.34M |
| Shareholder's equity | 337.90M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -91.80M |
| Capital expenditures (TTM) | 1.77M |
| Free cash flow (TTM) | -93.57M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -30.37% |
| Return on Assets | -24.02% |
| Return on Invested Capital | -29.80% |
| Cash Return on Invested Capital | -27.18% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.20 |
| Daily high | 2.40 |
| Daily low | 2.17 |
| Daily Volume | 1.64M |
| All-time high | 75.62 |
| 1y analyst estimate | 11.25 |
| Beta | 0.81 |
| EPS (TTM) | -1.39 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| NKTX | S&P500 | |
| Current price drop from All-time high | -96.83% | -0.89% |
| Highest price drop | -98.19% | -19.00% |
| Date of highest drop | 26 Mar 2025 | 8 Apr 2025 |
| Avg drop from high | -97.13% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
170.47M
Marketcap category
Small-cap
Description
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Employees
105
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page